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Abstract
Objective: Exenatide belongs to a new therapeutic class in the treatment of diabetes (incretin mimetics),
allowing glucose-dependent glycaemic control in Type 2 diabetes. Randomised controlled trial data suggest that
exenatide is as effective as insulin glargine at reducing HbA1c in combination therapy with metformin and
sulphonylureas; with reduced weight but higher incidence of adverse gastrointestinal events. The objective of this
study is to evaluate the cost effectiveness of exenatide versus insulin glargine using RCT data and a previously
published model of Type 2 diabetes disease progression that is based on the United Kingdom Prospective
Diabetes Study; the perspective of the health-payer of the United Kingdom National Health Service.
Methods: The study used a discrete event simulation model designed to forecast the costs and health outcome
of a cohort of 1,000 subjects aged over 40 years with sub-optimally-controlled Type 2 diabetes, following initiation
of either exenatide, or insulin glargine, in addition to oral hypoglycaemic agents. Sensitivity analysis for a higher
treatment discontinuation rate in exenatide patients was applied to the cohort in three different scenarios; (1)
either ignored or (2) exenatide-failures excluded or (3) exenatide-failures switched to insulin glargine. Analyses
were undertaken to evaluate the price sensitivity of exenatide in terms of relative cost effectiveness. Baseline
cohort profiles and effectiveness data were taken from a published randomised controlled trial.
Results: The relative cost-effectiveness of exenatide and insulin glargine was tested under a variety of conditions,
in which insulin glargine was dominant in all cases. Using the most conservative of assumptions, the cost-
effectiveness ratio of exenatide vs. insulin glargine at the current UK NHS price was -£29,149/QALY (insulin
glargine dominant) and thus exenatide is not cost-effective when compared with insulin glargine, at the current
UK NHS price.
Conclusion: This study evaluated the relative cost effectiveness of insulin glargine versus exenatide in the
management of Type 2 diabetes using a published model. Given no significant difference in glycaemic control and
applying the additional effectiveness of exenatide over insulin glargine, with respect to weight loss, and using the
current UK NHS prices, insulin glargine was found to be dominant over exenatide in all modelled scenarios. With
current clinical evidence, exenatide does not appear to represent a cost-effective treatment option for patients
with Type 2 diabetes when compared to insulin glargine.
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Background
The progression of Type 2 diabetes is driven by progressive
β-cell dysfunction and increased insulin resistance, which
results in hypoglycaemia due to difficulty of achieving gly-
caemic control. Typically, lifestyle modifications such as
diet and exercise fail to achieve and give way to the admin-
istration of oral hypoglycaemic agents (OHAs) in order to
maintain glucose control. In addition to tolerability issues
for patients, the inability of OHAs to stem the decline in
β-cell function  [1] commonly lead to the introduction of
exogenous basal insulin to maintain normoglycaemia [2].
Traditionally regarded as a drastic measure in Type 2 dia-
betes, physicians are increasingly favouring earlier intro-
duction of basal insulin to control hyperglycaemia and
minimise the associated micro- and macrovascular com-
plications of diabetes [3,4]. Whilst undoubtedly clinically
effective, use of insulin regimens also carries some prob-
lems, namely:
• an inability to control mealtime glucose excursion [5],
￿ increased risk of severe hypoglycaemia [6,7],
￿ the need for complicated dose-titration [8], and
￿ weight gain [9].
Hypoglycaemia of any severity has a profound effect on
patients' quality of life [7] and is regarded as the single
greatest obstacle to achieving normoglycaemia [10]. In
addition to reduced quality of life, hypoglycaemia results
in substantial direct medical cost and lost productivity
[11].
Insulin glargine (Lantus™) is an analogue of human insu-
lin with a prolonged duration of action and once-daily
dosing. In Type 2 diabetes, the principal emergent benefit
is significantly reduced risk of all forms of hypoglycaemia
over Neutral Protamine Hagedorn (NPH) [12]. However,
initiation of insulin glargine still requires careful dose
titration to an appropriate level over a period of time. This
is essential for successful treatment of diabetes and the
avoidance of hypoglycaemia [13]. However, recent trial
evidence has suggested that insulin glargine could be
introduced earlier to achieve glycaemic goals [14] and a
further study showed that adding insulin glargine to OHA
therapy had a positive effect on treatment satisfaction and
quality of life (QoL) without complaints related to
hypoglycaemia [15]. Insulin glargine is currently not rec-
ommended by the National Institute for Health and Clin-
ical Excellence (NICE) for routine use for people with
Type 2 diabetes, but can be considered for people with
Type 2 diabetes who require assistance from a third party
to administer their insulin injections, who have recurrent
symptomatic hypoglycaemic episodes or who would oth-
erwise need twice-daily basal insulin injections in combi-
nation with oral antidiabetic drugs. Using their own
model (based on United Kingdom Prospective Diabetes
Study (UKPDS) 68 [16]), NICE concluded that human
insulin analogues are the most cost-effective option and
glargine was estimated to be cost-effective in Type 2 diabe-
tes patients at increased risk of hypoglycaemia [17]; the
NICE guidelines are due to be reviewed and republished
in early 2009.
The incretin mimetics are emerging as a significant new
class of hypoglycaemic agents that regulate glucose home-
ostasis similarly to endogenous glucagon-like peptide-1
(GLP-1). Exenatide (Byetta™), the first such compound to
be licensed by the European Medicine Agency (EMEA)
[18], enhances glucose-dependent insulin secretion, regu-
lates glucagon release, and delays gastric emptying
thereby reducing hyperglycaemia in a similar manner to
GLP-1. Unlike the short-lived GLP-1, exenatide resists
metabolism by dipeptidyl peptidase-IV giving it a phar-
macokinetic profile suitable for chronic administration
[19]. Exenatide is recommended for use in the treatment
of Type 2 diabetes in combination with metformin, and/
or sulphonylureas in patients who have not achieved ade-
quate glycaemic control on maximally tolerated doses of
these oral therapies and is given twice daily by subcutane-
ous injection. Exenatide was approved by the Scottish
Medicines Consortium (SMC) in June 2007, as an adjunct
therapy to patients with Type 2 diabetes who, despite cur-
rently taking metformin and/or a sulphonylurea either
singly or in combination, fail to achieve adequate glycae-
mic control [20]. Exenatide, however, is not currently rec-
ommended by NICE for routine use for people with Type
2 diabetes [17] and should only be considered for people
with Type 2 diabetes, who have a body mass index (BMI)
over 35 kg/m2, specific problems arising from high
weight, inadequate blood glucose control (glycosylated
haemoglobin (HbA1c) >7.5 %), prescribed conventional
oral therapy and where other high cost therapies would
otherwise be commenced. Using their own model (based
on UKPDS 68 [16]), NICE estimated that exenatide was
not cost-effective in any scenario [17] and, furthermore,
exenatide has been linked with occurrences of acute pan-
creatitis [21].
The only published head-to-head randomised controlled
trial (RCT) [22] of exenatide versus glargine, reported sim-
ilar improvements in the overall glycaemic control in
patients with Type 2 diabetes sub-optimally controlled
with combination OHAs at maximal doses. For secondary
endpoints, patients treated with exenatide experienced
significantly fewer nocturnal hypoglycaemic events (0.9
vs. 2.4 events per patient per year; a 63% reduction), but
higher incidence of daytime hypoglycaemia (6.6 vs. 3.9
events per patient per year; a 69% increase) and achievedCardiovascular Diabetology 2008, 7:24 http://www.cardiab.com/content/7/1/24
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significant weight loss from baseline (Δ -2.3 kg), whereas
insulin glargine-treated subjects gained weight of a similar
magnitude (Δ +1.8 kg) by the study endpoint. The princi-
pal drawback reported in exenatide treated patients was
nausea (in 57.1% of subjects) and vomiting (in 17.4%),
which led to withdrawal of almost 10% of exenatide-
treated patients from the study protocol. This finding is
consistent with evidence from other published phase 3
placebo-controlled trials [23]. By comparison, less than
1% of those exposed to insulin glargine withdrew due to
adverse events. The most common adverse event reported
with insulin glargine was nasopharyngitis (in 9.0%).
Within this trial setting, however, the dosage of glargine
was very low with an average of 25 international units
(IU)/day. This does not reflect clinical practise, where the
dosage is typically 42 IU/KG [24]. A higher dose with
glargine will lead to better glycaemic control, but also
more weight gain and will have an effect on hypoglycae-
mic events [25,26]. Regarding patient reported outcomes,
Boye and colleagues published the patient reported out-
comes measured from the same head-to-head trial [22]
and showed no significant difference in improvement of
health utility or quality of life [27].
The increasing global financial burden of chronic health
conditions is fuelling a rising demand for value for money
when introducing new health technologies. In line with
many other countries, in the United Kingdom (UK), NICE
currently accepts as cost-effective, "those interventions
with an incremental cost-effectiveness ratio of less than
£20,000 per QALY (quality adjusted life year) and that
there should be increasingly strong reasons for accepting
as cost effective interventions with an incremental cost-
effectiveness ratio of over £30,000 per QALY [28]." A
recently published study of Ray et al. [29] showed
exenatide to have a cost-effectiveness ratio of £22,420 vs.
insulin glargine; however, a major limitation of this study
was that it used an estimated UK cost of exenatide based
on the US price. The study reported exenatide as domi-
nant (less costly and more effective) when marketed at
20% of the US price in the UK. The study of Ray et al. used
cohort details from the Heine trial [22] that were then
applied to a previously published cost effectiveness model
[30], the CORE Model.
The objective of this analysis was to prospectively evaluate
the cost-effectiveness of exenatide from a UK NHS per-
spective, using insulin glargine as a comparator and the
current UK NHS price for exenatide and also applying the
cohort profiles and published data from the Heine trial
[22]. The model, which has been previously published
[31], used to evaluate the cost-effectiveness was a discrete
event simulation (DES) model for patients with Type 2
diabetes using UKPDS-derived risk functions [16] and a
multivariate regression model for the utility associated
with hypoglycaemia [7].
Methods
Modelling approach and model
This evaluation was undertaken within the context of the
UK National Health Service (NHS), and used the NHS as
its perspective (payer's perspective). The method used was
a cost-utility analysis (CUA) intended to determine the
cost per quality adjusted life years gained (QALYs gained)
comparing exenatide to insulin glargine as adjunct ther-
apy to maximal doses of metformin and sulphonylurea in
Type 2 diabetes.
The modelling approach used was a discrete event simula-
tion (DES) model of people with Type 2 diabetes using
UKPDS-derived risk functions for development of vascu-
lar complications [16] and a multivariate regression
model for the utility decrement associated with hypogly-
caemia [7]. The details of the model and its validation
have been published [32], but a brief description is given
below.
The model simulates a cohort of 1000 subjects over a 40-
year time horizon. The specific events modelled were
ischaemic heart disease (IHD), myocardial infarction
(MI), congestive heart failure (CHD), stroke, blindness in
one eye, end stage renal disease (ESRD) and amputation,
in addition to diabetes-related and all-cause mortality;
furthermore, the model additionally predicts severe, noc-
turnal, and symptomatic hypoglycaemic events. The
results presented represent an average of one hundred first
order Monte Carlo simulations. The baseline characteris-
tics of the subjects from Heine trial [22] (Table 1) were
applied and are generally consistent with the profile of
Table 1: Baseline patient characteristics.
Variable Type 2 diabetes
Age (years)† 59
Gender (% male)† 56%
BMI (kg/m2)† 31.9
Weight (kg)† 89.8
Height (metres)† 1.67
Ethnicity (% black)† 1%
Total cholesterol (mmol/L)‡ 5.2
HDL cholesterol (mmol/L)‡ 1.04
Systolic blood pressure (mmHg)‡ 136
HbA1c (%)† 7.1
Peripheral vascular disease (%)‡ 30%
Smoking (%)‡ 0
Risk of severe hypoglycaemia* 0.462
Number of nocturnal hypos (year)† 2.4
Number of symptomatic hypos (year)† 6.8
†Data from Heine et al[22], ‡ data from UKPDS baseline cohort[16], * 
data from Leese et al[6]Cardiovascular Diabetology 2008, 7:24 http://www.cardiab.com/content/7/1/24
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insulin-treated patients with Type 2 diabetes in the UK, as
older and obese (Body Mass Index (BMI) greater than 30
kg/m2).
The model first simulates treatment of the cohort with
basal insulin glargine plus OHAs. At the beginning of each
time period, checks were made for specific fatal or non-
fatal events. The order in which these events occurred was
randomised. If a fatal event occurred, all costs, life years
and quality adjusted life years were accumulated and the
simulation ended for that individual. The simulation then
selects the next individual and the process begins again.
Assuming a subject does not die in any specific year then
following the 'check for events' stage, a simulated subject's
disease state is updated and any appropriate decrement in
health utility was then applied together with associated
costs. The simulation time clock is then advanced and if
the end of the simulation time horizon has been reached,
the simulation ended for that individual and the process
starts again with the next individual. Once all individuals
had been simulated, the process ends and all summary
statistics are calculated for that particular run of the
model.
The second run of the model for treatment with exenatide
plus OHAs utilised exactly the same patient cohort data as
the first run but applied the alternative treatment effects
and costs (Table 2). After applying any differential effects
to the patient data, the model was then re-initialised and
run through in exactly the same manner as for the first
run.
Effectiveness
Three significant endpoints emerged from the Heine trial
[22] which were included in the model as treatment
effects. Overall, patients in the exenatide group had a
higher rate of hypoglycaemic events then patients in the
insulin glargine group (7.3 events/patient-year vs. 6.3
events/patient-year). Nocturnal hypoglycaemia was 63%
lower in the exenatide group than the insulin glargine
group (0.9 events/patient-year vs. 2.4 events/patient-
year), but patients in the exenatide group had a 69%
higher incidence of daytime hypoglycaemia than patients
the insulin glargine group (6.6 events/patient-year vs. 3.9
events/patient-year). No differences in severe hypoglycae-
mia were recorded and therefore the model was run using
previously published rates [6].
At the 26-week trial endpoint average patient weight was
4.1 kg lower in the exenatide group compared to the insu-
lin glargine group. For each group, change in weight (kg)
over time (weeks) had begun to plateau by the study end-
point, a pattern echoed by the long-term extension trials
of exenatide [23]. Thus, this difference was conservatively
applied as the maximum weight improvement for
exenatide patients. Differential levels of HbA1c were not
modelled as the trial showed no significant difference in
glycaemic control between insulin glargine and exenatide.
Finally, discontinuation rates due to adverse events (Δ
8.9% of intention-to-treat (ITT) patients) were modelled
using three approaches: either completely ignored;
exenatide-discontinuations removed from analysis; and
exenatide discontinuations switched to insulin glargine.
Estimates of financial costs
The financial costs applied to the simulation model are
detailed in Table 3, and summarised as follows. Costs of
medical treatment were obtained from UK sources and
were indexed to year 2007 with UK Treasury rates [32].
Treatment and comparator Insulin glargine cost was cal-
culated on a per kilogram basis, costed at the current UK
weighted average wholesale prices for Lantus across the
different preparations [33] to reflect the UK market. A
0.28 IU/kg/day dose regimen was assumed for insulin
glargine, based on the average daily requirement reported
at the study endpoint [22]. In common with the Heine
trial protocol [22], where daily glucose monitoring was
not required for patients assigned to receive exenatide, the
Table 2: Treatment and comparator costs applied in the model.
Description Cost Source
Insulin glargine group
price per 1000 IUs £26.00 BNF No. 55[33]
Glucose test strip £0.302 2006 DoH Prescription Cost Analysis[34]
Lancet £0.055 2006 DoH Prescription Cost Analysis[34]
Exenatide group
10 ug BD, per 28 days £68.24 BNF No. 55[35]
Both groups
Metformin per day
(500 mg QDS)
£0.21 BNF No. 55[33]
Gliclazide per day
(320 mg per day)
£0.25 BNF No. 55[33]Cardiovascular Diabetology 2008, 7:24 http://www.cardiab.com/content/7/1/24
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additional cost of one reagent tests strip and one lancet
per day was applied. In each case, the weighted average
cost was derived from the 2006 Department of Health
(DOH) Prescription Cost Analysis [34]. As neither blood
glucose testing meters nor finger-pricking devices are
available on the NHS, they did not represent a cost to the
health payer and were excluded from the analysis. The
exenatide treatment cost was estimated using the UK mar-
ket launch price [35]. 5 microgram twice daily (BD) was
assumed for initiation for a month and after this a 10
microgram BD maintenance dose, this follows the NHS
recommendations [36]. In both the insulin glargine and
exenatide simulated cohorts the cost of metformin and
gliclazide (representing 1st line sulphonyureas) adminis-
tered were modelled at their respective maximum daily
dosages [33]. The model assumes these first line therapies
are well tolerated to the maximum dose and patient man-
agement will typically involve titrating to the maximum
daily dose and then subsequent therapy will be added to
this and titrated appropriately.
Macrovascular event costs Macrovascular event costs are
split into either fatal or non-fatal costs and were applied
in the year in which the event occurred. Maintenance costs
for those subjects surviving were applied in all subsequent
years until either the end of the simulation time horizon
or until the subject died.
Blindness (in one eye) Subjects were assumed to incur
blindness in one eye only. The initial cost related to the
event was assumed to be equal to zero, with subsequent
maintenance costs applied annually thereafter from pub-
lished data [37].
Nephropathy Dialysis costs were annual weighted mean
costs for peritoneal dialysis (£15,534; 71%) and haemo-
dialysis (£33,516; 29%) [38].
Peripheral vascular disease was modelled as the occur-
rence of an amputation and had a single cost associated
with the event and a subsequent annual maintenance
cost.
Severe hypoglycaemia costs are applied to severe
hypoglycaemia events only and are based on the costs of
hospitalised treatment reported in Tayside, UK. The Dia-
betes Control and Complications Trial (DCCT), estimated
that 20% of all severe hypoglycaemic episodes result in a
hospital intervention, either emergency room attendance
or inpatient hospitalization. The most comprehensive
data relating to treatment modality of severe hypoglycae-
mic episodes is reported by Leese et al. [6], from their
observational study of registered diabetics in Tayside,
Scotland, UK. In this study, 34% of severe hypoglycaemia
episodes were managed by an ambulance attendance,
46% by accident & emergency (A&E) consultation, and
the remaining 20% were hospitalized as inpatients, repre-
senting 5% of all estimated severe hypoglycaemia (hospi-
talized or not) for this population. Over the 12-month
study period, Leese et al report 244 episodes totalling
Table 3: Event, Maintenance and therapy costs (indexed to £UK 2007)
Variable Cost Source
Ischaemic Heart Disease, fatal event £0 UKPDS Study No.65†
Ischaemic Heart Disease, Non-fatal event £2,388 UKPDS Study No.65†
Ischaemic Heart Disease, Maintenance £601 UKPDS Study No.65†
Myocardial Infarction, Fatal event £1,404 UKPDS Study No 65†
Myocardial Infarction, Non-fatal event £4,961 UKPDS Study No.65†
Myocardial Infarction, Maintenance £566 UKPDS Study No.65†
Congestive Heart Failure, Fatal event £0 UKPDS Study No.65†
Congestive Heart Failure, Non fatal event £2,707 UKPDS Study No.65†
Congestive Heart Failure, Maintenance £769 UKPDS Study No.65†
Stroke, Fatal event £4,124 UKPDS Study No.65†
Stroke, Non-fatal event £2,885 UKPDS Study No.65†
Stroke, Maintenance £304 UKPDS Study No.65†
Blindness, Event 0 O'Brien et al. [37]
Blindness, Maintenance £1,013 O'Brien et al. [37]
Dialysis, Event and Maintenance £20,049 Baboolal et al. [38]
Amputation, Fatal event £10,311 UKPDS Study No.65†
Amputation, Non-fatal event £10,311 UKPDS Study No.65†
Amputation, Maintenance £366 UKPDS Study No.65†
Hypoglycaemia, Event £93.85 Leese GP et al. [6]; DCCT hypoglycaemia report*
† Data from: Clarke P, Gray A, Legood R, Briggs A, Holman R: The impact of diabetes-related complications on healthcare costs: results 
from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabetic Medicine 2003, 20:442–450.
* Data from: The DCCT Research Group: Epidemiology of severe hypoglycemia in the diabetes control and complications trial. 
American Journal of Medicine 1991, 90:450–459.Cardiovascular Diabetology 2008, 7:24 http://www.cardiab.com/content/7/1/24
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£92,078 of healthcare resources, some £377.37 per epi-
sode. Given this represents only a fifth of all severe epi-
sodes [39], the average known cost across all episodes in
1998 (year of Leese' data collection) is estimated to be
£75.47. Indexed to 2007, the average cost of treating all
DCCT-defined severe hypoglycaemia is £93.85.
Health-related utility
Utility estimates were taken from either the UKPDS study
[16], or generated via the Health Outcomes Data Reposi-
tory (HODaR) database [40,41]. The utility decrements
associated with each specified event have been specified
previously [31] and are shown in Table 4. The model
assumes that multiple diabetes related complications
have an additive effect on utility; that is, the combined
utility decrement for a person experiencing both an MI
and stroke event would be the sum of the two individual
utility values. The same utility decrement was applied in
years subsequent to the year in which the event occurred.
Utility associated with hypoglycaemia events is handled
somewhat differently. Statistical models were developed
that related the frequency and severity of hypoglycaemia
to fear of hypoglycaemia, and subsequently to changes in
health-related utility [7]. The relationship between
hypoglycaemia and utility was modelled using a two stage
approach in which equations were derived describing the
relationship between hypoglycaemia and the fear of
hypoglycaemia (measured via the Hypoglycaemia Fear
Score (HFS)). Subsequently the relationship between
changes in HFS was related to health utility, measured
using the EQ5D [42]. The equations showed that the mar-
ginal effects of the occurrence of at least one severe
hypoglycaemic episode was associated with a 5.881
change in HFS score and that unit changes in the natural
log of the number of symptomatic events and the square
root of the number of nocturnal events was associated
with a 1.773 and 1.054 change in the HFS score respec-
tively. Each unit increase in HFS was associated with a util-
ity of decrement of 0.008 (for severe and symptomatic)
and 0.007 for nocturnal hypoglycaemia. The disutility
associated with the fear of hypoglycaemia is applied
throughout each simulated year if a hypoglycaemic event
occurs; if simulated patients do not experience an event
then no disutility is applied. Hypoglycaemia is the only
adverse event accommodated in the model; the analysis
does not model complications such as acute pancreatitis
and therefore is somewhat conservative with respect to
glargine.
Important differences exist between exenatide and
glargine that may also affect quality of life; in particular,
changes in weight and a different side effect profile. A
number of studies have shown exenatide to be associated
with weight reduction [43,44] whilst insulin is associated
with weight gain [45,46]. Furthermore, exenatide has
been shown to have more frequent gastrointestinal side
effects. A number of studies have reported changes in util-
ity associated with changes in weight (or more specifi-
cally, BMI). Importantly, these studies are cross-sectional
in design and do not capture changes in utility associated
with an individuals' experience of their own weight loss/
gain and, therefore, the application of such utility gains
may overstate the effects of weight change. This view is
corroborated by results from a randomised trial compar-
ing patient reported outcomes in 549 subjects ran-
domised to either insulin glargine or exenatide. Despite
expected differences in weight change, side effect profile
and dosing frequency, insulin glargine patients exhibited
a non-significant increase in EQ5D compared patients
receiving exenatide (0.03 versus 0.02 utility gain, p =
0.35) [47].
The results presented here did not accommodate any util-
ity changes associated with gastrointestinal side effects or
weight change. Furthermore, consistent with longitudinal
studies assessing health utility and insulin initiation, no
utility decrement was applied to therapy type [48].
Other economic analysis details
All prices are all adjusted to 2007 values (UK£) using the
UK Treasury gross domestic product (GDP) deflator for-
mula [32]. Where necessary, costs and benefits were dis-
counted at 3.5% per year in accordance with current NICE
guidance [28].
Results
Number of end points forecast in each arm
The model was designed to output the frequency (per
1,000 patients) in each of a range of pertinent vascular
events and mortality that are listed in Table 5 for the three
main scenarios.
Ignoring discontinuation rates
In the first scenario where no exenatide treatment discon-
tinuations was considered, there was an overall difference
of 21,359 nocturnal episodes of hypoglycaemia, in favour
of exenatide, but 38,808 more daytime episodes of
hypoglycaemia for patients treated with exenatide. Over-
Table 4: Clinical endpoints modelled and utility decrements 
applied
Health state Utility Source
Ischaemic Heart Disease -0.09 UKPDS Study No.68[16]
Myocardial Infarction -0.055 UKPDS Study No.68[16]
Congestive Heart Failure -0.108 UKPDS Study No.68[16]
Stroke -0.164 UKPDS Study No.68[16]
Blindness in one eye -0.074 UKPDS Study No.68[16]
ESRD -0.305 Lee et al. [42]
Amputation -0.28 UKPDS Study No.68[16]Cardiovascular Diabetology 2008, 7:24 http://www.cardiab.com/content/7/1/24
Page 7 of 12
(page number not for citation purposes)
all 24.5 severe hypoglycaemic events were predicted for
patients treated with exenatide. The biggest difference in
vascular endpoints occurred for congestive heart failure
(CHF), where use of exenatide results in 7.7 fewer events
on average; this difference being driven by the improved
BMI profile associated with exenatide.
Removing patients discontinuing from the analysis
With exenatide treatment discontinuations excluded from
the analysis, the number of clinical endpoints predicted
are fewer in the exenatide group (with the exception of
daytime hypoglycaemic events); however, this observa-
tion is due to fewer patients available in the model to
experience clinical endpoints.
Switching patients discontinuing exenatide to insulin 
glargine
Switching exenatide discontinuations to insulin glargine
produces similar results to ignoring discontinuation rates
altogether. The number of nocturnal hypoglycaemic
events with exenatide reduces to 19,465 and the number
of additional daytime hypoglycaemic events increases by
35,402. The number of expected CHF events avoided with
exenatide is 6.87 when compared with insulin glargine.
Under these conditions, mortality due to macrovascular
events is still favourable to exenatide with 4.0 deaths
avoided, but this scenario is the least positive result to
exenatide compared with 4.7 macrovascular deaths saved
in the baseline scenario and 43.0 macrovascular deaths
saved when exenatide treatment failures are excluded.
Total costs and QALYS forecast in each arm
Applying the current UK price of exenatide, total treat-
ment costs over the simulation period associated with
exenatide use were significantly higher than for insulin
glargine. Ignoring discontinuations rates resulted in the
discounted total costs (per 1,000 patients) of £14,567,526
and £9,280,312 for exenatide and insulin glargine, respec-
tively (Δ ≈ £5.3 M, Table 5). The total and difference in
quality adjusted life years (QALYs) is also listed in Table
5; with 160 fewer QALYs associated with exenatide.
Although there were fewer nocturnal hypoglycaemic
events associated with exenatide, their contribution to
improving quality of life was offset by higher daytime
Table 5: The forecast frequency of vascular endpoints and cost-effectiveness using insulin glargine or exenatide per 1,000 patients over 
40 years under the three discontinuation scenarios.
No discontinuation Failures excluded Failures switched
Exenatide Glargine Δ Exenatide Glargine Δ Exenatide Glargine Δ
Macrovascular
Ischaemic Heart Disease 122.2 121.2 -1.06 111.1 121.4 10.32 121.8 121.4 -0.36
Myocardial Infarction 387.4 388.2 0.82 351.9 387.7 35.79 386.1 387.7 1.61
Congestive heart Failure 84.9 92.6 7.68 77.7 92.3 14.59 85.4 92.3 6.87
Stroke 98.9 99.7 0.74 90.1 98.3 8.19 99.2 98.3 -0.89
Microvascular
Retinopathy 55.5 55.4 -0.03 50.7 55.4 4.73 55.3 55.4 0.11
Nephropathy 14.1 13.8 -0.29 12.7 14.1 1.41 14.1 14.1 -0.01
Neuropathy 12.9 12.9 0.04 11.8 12.9 1.13 13.1 12.9 -0.14
Hypoglycaemia events
Nocturnal 12901.2 34259.8 21358.6 11754.3 34269.6 22515.3 14804.9 34269.6 19464.7
Symptomatic 94479.7 55672.2 -38807.5 86080.9 55688.1 -30392.8 91090.4 55688.1 -35402.3
Severe 6622.0 6597.5 -24.5 6036.2 6598.1 561.9 6626.2 6598.1 -28.2
Fatal
Macrovascular 453.5 458.2 4.68 412.8 457.3 44.53 453.3 457.282 4.008
Microvascular 12.7 12.7 -0.02 11.6 12.8 1.18 12.9 12.752 -0.154
Other 532.8 528.1 -4.68 486.0 529.0 42.99 532.8 529.0 -3.845
Cost effectiveness
Discounted costs £14,567,526 £9,280,312 £13,255,912 £9,296,371 £14,092,624 £9,296,371
Discounted QALYS 7,683 7,864 7,000 7,865 7,703 7,865
ICER (£/QALY) Dominant (-£29,149) Dominant (-£4,579) Dominant (-£29,657)
Note: the model takes an average of a series of runs in order for the resultant values to become stable. In taking this average non-integer values can 
be generated.Cardiovascular Diabetology 2008, 7:24 http://www.cardiab.com/content/7/1/24
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events and overall higher severe hypoglycaemic events
when compared to insulin glargine. Using the current
multivariate hypoglycaemia model each nocturnal
hypoglycaemic event results in a 0.68% decrement in util-
ity, whereas one severe hypoglycaemic event leads to a
4.40% utility decrement [7].
Incremental cost effectiveness ratios
Under the no discontinuation scenario, the mean incre-
mental cost effectiveness ratio (ICER) was-£29,149 per
QALY gained, with insulin glargine being less costly and
more effective than exenatide. Under the most conserva-
tive scenario of excluding exenatide failures, the domi-
nance of insulin glargine persisted with a mean ICER of -
£4,579 per QALY gained. The scenario where exenatide
failures were switched to insulin glargine produced simi-
lar results with insulin glargine remaining cheaper and
more effective than exenatide (mean ICER of -£29,657 per
QALY gained).
Sensitivity analysis
As a sensitivity analysis, the input factors for the model
were varied to reflect long term outcomes and clinical
practice for glargine and exenatide. Open label extension
of exenatide trials showed that the glycaemic control in
the long term was similar to the effect shown in the Heine
trial. However weight reduction was continuing up to a
maximum of 5.3 kg over 3 years. There was no evidence of
the rate of hypoglycaemic events in published the open
label extensions [49-51]. Glargine studies applying a more
clinically relevant dosage scenario – on average a dose of
53 IU/day – showed that glycaemic control could be more
improved than shown in the Heine trial; on average a fur-
ther reduction of 0.65% in HbA1c. On the other hand
weight increased on average by 3.0 kg and nocturnal
hypoglycaemic events increased on average to 3.55
events/patient-year and symptomatic events on average to
5.65 events/patient-year. Using the same hypoglycaemic
rates for exenatide as reported in the Heine trial, the noc-
turnal hypoglycaemia rate would be 75% lower in the
exenatide group than the insulin glargine group, and inci-
dence of daytime hypoglycaemia would be 17% higher in
the exenatide group than in the insulin glargine group.
Applying this evidence of glycaemic control, weight con-
trol and dosage to the model showed that exenatide in
comparison to glargine was still estimated to be more
costly and a less effective option with a cost-effectiveness
ratio of £6,365 (glargine dominant). Using the evidence
of increased hypoglycaemic events when using a higher
dosage of glargine the results were similar and exenatide
in comparison to glargine was still estimated to be more
costly and a less effective option with a cost-effectiveness
ratio of £6,884 (glargine dominant). The complete results
of the two sensitivity scenarios are shown in Table 6.
Discussion
For this analysis, a previously published UK diabetes Type
2 model was used to evaluate the introduction of
exenatide in patients with sub-optimally controlled Type
2 diabetes to the UK NHS. As a comparator, insulin
glargine, a long-acting once daily human insulin ana-
logue, was chosen. The results of the study reflect the long-
term projection of the findings of the Heine trial [22].
Using the baseline profiles and treatment effects outlined
here the economic evaluation conducted found that insu-
lin glargine dominated exenatide.
A recently published study of Ray et al. [29] evaluating the
cost-effectiveness of exenatide vs. insulin glargine using
the same input from the Heine trial [22] showed different
results to our findings. Ray et al. demonstrated that
exenatide has a cost-effectiveness ratio of £22,420 vs.
insulin glargine at an estimated 100% US price. Further-
more, it was estimated that exenatide is dominant (cost
and QALY saving), when marketed at 20% of the US price
in the UK. A cost-effectiveness ratio below the recom-
mended £20,000/QALY [28] was achieved at 80% of the
US price, which approximately equals the current UK mar-
ket price. Using the same Heine trial data [22] as utilised
in this study, Ray et al. [29] estimated that exenatide is a
cost-effective treatment option in patients with sub-opti-
mally controlled Type 2 diabetes in the UK. Ray et al. [29]
modelled their baseline scenario (100% US price) over a
time horizon of 35 years and reported higher direct med-
ical costs for exenatide and insulin glargine £29,401 and
£19,489 per patient respectively) and higher QALYs
(14.62 and 14.51 per patient respectively) than we
derived in our analyses for exenatide and insulin glargine
(cost: (£14,568 and £9,280 per patient respectively;
QALYs: 7.68 and 7.86 per patient respectively) using a
time horizon of 40 years. Both studies showed that life-
time medical costs are higher for patients with exenatide
and insulin glargine and Ray et al.'s [29] estimate was
much higher over a shorter time period than ours.
The main difference between the outcomes reported by
Ray et al. [29] and our own study were the QALY estimates
with Ray et al. [29] estimating a QALY gain for patients
treated with exenatide, while our analysis showed a QALY
gain for patients treated with insulin glargine. Reviewing
the input factors for the model of Ray et al. [29] showed
that the authors used more evidence from the Heine trial
[22] in favour of exenatide than we used in our study.
While there is clear evidence for a difference in hypogly-
caemic events, weight loss and patients with nausea, there
was no clear evidence of any significant difference in other
factors favouring exenatide. Ray et al. [29] included lower
systolic blood pressure (SBP), lower total cholesterol
(TC), lower low-density lipoprotein (LDL) and lower trig-
lycerides in patients treated with exenatide. These risk fac-Cardiovascular Diabetology 2008, 7:24 http://www.cardiab.com/content/7/1/24
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tors are influential predictors of future diabetes-related
complications and improvements reported in the Heine
trial [22] were non-significant. We did not see this as evi-
dence for a significant treatment effect and therefore did
not include these in our model. As outlined in the meth-
ods section, we did not include disutility associated with
weight gain, gastrointestinal side effects or insulin initia-
tion. The justification for this approach being the analysis
of patient reported outcomes in a head to head compari-
son of exenatide and glargine. Furthermore, while cross
sectional studies have demonstrated a disutility of insulin
use compared to oral agents [52], prospective longitudi-
nal studies have shown that insulin therapy does not
impact on quality of life [53].
The major drawback of the Heine trial [22] was that the
dosing of glargine did not reflect clinical practice. Within
the trial design, the dosing of glargine was very low, with
an average of 25 IU/day. A higher dose of glargine natu-
rally leads to improved glycaemic control, but also more
weight gain and, potentially, hypoglycaemic events. Our
sensitivity analyses showed that applying long term data
to the exenatide arm and a more clinically relevant dosing
scenario for glargine produced results consistent with the
base case findings.
As with all modelling simulations, our economic evalua-
tion has a number of strengths and weaknesses. The
model can only be as reliable as the predictive algorithms
and other data that were used in its construction. The
model was based on contemporary data largely drawn
from the same source – the United Kingdom Prospective
Diabetes Study; however, the dependence of our findings
on the UKPDS model is not without drawbacks. In partic-
ular, the UKPDS outcomes model does not completely
capture the complexities of all diabetes related complica-
tions. For example, complications such as peripheral neu-
ropathy, ulceration, gross proteinuria or proliferative
retinopathy and macular oedema are handled crudely,
primarily due to insufficient patient numbers experienc-
ing these events in the UKPDS study. This is largely due to
the inclusion criteria of the UKPDS study in which
patients were newly diagnosed with Type 2 diabetes with
no pre-existing cardiovascular complications. Type 2 dia-
Table 6: Sensitivity analysis for the forecast of frequency of vascular endpoints and cost-effectiveness using insulin glargine or 
exenatide per 1,000 patients over 40 years (no discontinuation scenario).
Long term scenario
 (without hypoglycaemia risk change)
Long term scenario
 (with hypoglycaemia risk change)
Exenatide Glargine Δ Exenatide Glargine Δ
Macrovascular
Ischaemic Heart Disease 122.1 115.2 -6.95 122.1 115.2 -6.95
Myocardial Infarction 387.2 367.1 -20.12 387.2 367.1 -20.12
Congestive heart Failure 78.2 87.2 9.07 78.2 87.2 9.07
Stroke 97.5 95.7 -1.86 97.5 95.7 -1.86
Microvascular
Retinopathy 55.8 49.2 -6.59 55.8 49.2 -6.59
Nephropathy 14.0 14.0 0.01 14.0 14.0 0.01
Neuropathy 13.1 10.1 -3.04 13.1 10.1 -3.04
Hypoglycaemia
 events
Nocturnal 12,749 35,113 22,364 12,742 51,939 39,197
Symptomatic 94,627 57,059 -37,568 94,907 82,663 -12,244
Severe 6,626.5 6,760.3 133.8 6,626.5 6,760.3 133.8
Fatal
Macrovascular 449 428.4 -20.5 449 428.4 -20.5
Microvascular 13.1 11.2 -1.91 13.1 11.2 -1.91
Other 536.8 559.4 22.59 536.8 559.4 22.59
Cost effectiveness
Discounted costs £14,552,192 £12,505,945 £14,552,192 £12,505,945
Discounted QALYS 7,688 8,009 7,687 7,984
ICER (£/QALY) Dominant (-£6,365) Dominant (-£6,884)Cardiovascular Diabetology 2008, 7:24 http://www.cardiab.com/content/7/1/24
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betes, however, is primarily characterised by macrovascu-
lar complications and the equations published from this
study represent a robust approach to describing the rela-
tionship between the major complications occurring in
Type 2 diabetes and modifiable risk factors. No modelled
economic evaluation can ever provide point estimates
that are demonstrably precise; nevertheless, the fact that
exenatide is significantly more costly than insulin
glargine, but provides only marginal benefits with respect
to BMI provides some degree of confidence that the con-
clusions presented here are reliable.
This study strictly applied those statistically significant dif-
ferences between exenatide and insulin glargine emergent
reported by Heine et al [22]. Although not necessarily an
accurate prediction of the performance of exenatide in
day-to-day practice, it is, nevertheless, consistent with
NICE economic modelling guidance [28], and therefore
appropriate. The study did not include utility estimates
regarding weight changes and adverse events due to treat-
ment. Published utility data related to weight changes are
not well reported, but preliminary analyses of HODaR
data [40], including longitudinal weight and utility data
suggested that utility changes start to become significant if
a patient gains/loses a great amount of weight (>5 kg) and
it is dependent on the initial weight (the higher the BMI
the more likely the patient benefit from weight loss). Cer-
tain other factors not reported by the Heine trial [22]
could also have had an impact on these outcomes. For
example, what was the utility decrement associated with
nausea and vomiting in the exenatide group? Did the sig-
nificant weight loss among exenatide-treated subjects
improve utility, in spite of gastro-intestinal symptoms,
and was the weight loss a result of nausea, pancreatic and
other gastro oesophageal problems? How did lipid pro-
files change as a result of weight loss experienced in the
exenatide arm? At the time of writing, these data are not
available in the public domain but, in their absence, it is
reasonable to conservatively assume there were no signif-
icant differences between the groups otherwise they
would presumably have been reported in the trial-related
publication.
Conclusion
This study could have a number of implications for policy
makers. Given therapeutic equivalence of exenatide and
insulin glargine concerning glycaemic control it is likely
that a forthcoming NICE appraisal of exenatide possibly
would apply the lower £20,000 threshold. This economic
evaluation showed that glargine, when used in the treat-
ment of Type 2 diabetes patients, was dominant in com-
parison to exenatide. Maintaining the current UK price
difference between insulin glargine and exenatide, the rec-
ommendation of exenatide should be considered cau-
tiously as a cost-effective alternative to insulin glargine for
tertiary treatment of Type 2 diabetes given the evidence
present for exenatide.
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